
Arrowhead Secures Australia TGA Approval for REDEMPLO® (plozasiran) in FCS
Arrowhead Pharmaceuticals Secures TGA Approval for REDEMPLO® (plozasiran) in Australia, Broadening Access for Patients with Familial Chylomicronemia Syndrome (FCS) Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has announced a significant regulatory milestone with the approval of REDEMPLO by Australia’s Therapeutic Goods Administration…












